Table 2.
N1 component latency and amplitude tabulated as standard and deviant across vehicle and ketamine treatments.
| N1 only | Vehicle |
Ketamine 30 mpk |
||
|---|---|---|---|---|
| ERP | Latency (ms) | Mean amplitude (μV) | Latency (ms) | Mean amplitude (μV) |
| Standard10 min | 50.2 ± 2.0 | 6.7 ± 1.2 | 67.5 ± 2.9*** | 8.1 ± 1.8 |
| Standard30 min | 54.3 ± 2.2 | 5.2 ± 1.5 | 58.3 ± 2.3 | 8.5 ± 1.7 |
| Standard60 min | 52.4 ± 2.4 | 5.5 ± 2.1 | 53.4 ± 2.9 | 8.2 ± 1.9 |
| Two-way ANOVA | Treatment; F(1) = 15.67; P = 0.0003 | Treatment; F(1) = 5.55; P = 0.02; | ||
| Treat × Time; F(2) = 7.03; P = 0.0022 | Treat × Time, ns | |||
| Time, ns | Time, ns | |||
| Deviant10 min | 46.2 ± 1.7 | 10.7 ± 1.6 | 65.4 ± 2.5*** | 10.4 ± 3.2 |
| Deviant30 min | 50.2 ± 1.8 | 9.7 ± 1.6 | 57.3 ± 2.4 | 14.0 ± 2.6 |
| Deviant60 min | 50.8 ± 1.7 | 11.4 ± 2.5 | 49.5 ± 3.3 | 10.4 ± 1.5 |
| Two-way ANOVA | Treatment; F(1) = 21.8; P < 0.0001 | Treatment, ns | ||
| Treat × Time; F(2) = 11.2; P = 0.0001 | Treat × Time, ns | |||
| Time, ns | Time, ns | |||
***Indicate p < 0.001 (Bonferroni post-tests) when compared to corresponding value under vehicle condition. Note a robust latency delay and an augmentation of amplitude (standard only) under ketamine.